Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…
Why it matters
The findings suggest that combining osimertinib with chemotherapy may enhance treatment outcomes for patients with specific genetic mutations in advanced NSCLC, potentially guiding personalized treatment strategies.